Hold CL with widened stop to $89.86 and covered-call overlay to address five consecutive zero/negative alpha decisions
Hold CL with tightened conviction but widened stop to $89.86; do not add at $91.95 due to symmetric R/R and insufficient yield; add only on confirmed breakout above $94.20 or constructive reversal at $89.86; implement covered-call overlay at $94-$95 to harvest carry given five consecutive decisions with zero/negative alpha.
| Position | Action |
|---|---|
| Confirmed close below $89.86 on >3M volume | Trim 25% position |
| Regime of indecision with passive Hold leaking alpha | Sell covered calls at $94-$95 strike to harvest defensive carry |
CL is a Dividend King with reaccelerating revenue, expanding FCF, fortress balance sheet, and defensive profile that becomes MORE valuable in a higher-for-longer rate environment; the technical consolidation is a launchpad, not a ceiling.
| Indicator | Value | Signal |
|---|---|---|
| 200 SMA | 85.86 | bullish |
| 50 SMA | 91.14 | bullish |
| 10 EMA | 92.42 | bearish |
| MACD | 0.38 | bearish |
| MACD Signal | 0.43 | bearish |
| MACD Histogram | -0.05 | bearish |
| RSI | 49.91 | neutral |
| ATR | 2.16 | neutral |
| Bollinger Middle (20 SMA) | 92.03 | neutral |
| VWMA | 92.23 | bearish |
Support: 89.86 · 91.14 | Resistance: 92.42 · 94.2
The stock is consolidating within a $4.34-wide Bollinger Band range ($89.86–$94.20) after recovering from a March 2026 selloff that bottomed near $83. The 50 SMA > 200 SMA golden cross remains in force, confirming the long-term uptrend, but short-term momentum has rolled over with MACD crossing below its signal line and price slipping below the 10 EMA. Volume has dried up to the lowest level in 30 sessions (2.43M shares), offering no confirmation of directional bias. RSI sits at equilibrium (49.91) and ATR is contracting (2.16 from 2.55), reinforcing the mean-reversion regime. Recommended action is HOLD—await either a close above $93.50 with volume >4M for a bullish entry, or a close below $91.00 with RSI < 45 for a bearish entry, before initiating new positions.
This report is AI-generated for informational and educational purposes only and is not investment advice or a recommendation to buy or sell any security. Full disclaimer.
When: Price bounces at $89.86 with MACD reset
Then: Add exposure
Q2 numbers directly refute the 'margin contraction' narrative
↩ rebuts: “Bear concern: 'Q2 margin contraction' — year-ago comp distorted by $929M impairment; underlying EBITDA grew; strip out the noise.”
EV: ~11% total return · concedes: Recession probability consensus is 8% — if a recession occurs, CL could reach $85; 2019 insider option exercise ($6M retained) is routine, not a bearish signal
CL at $91.95 is a poor risk/reward because the earnings recovery is already priced in, momentum is breaking down, and macro headwinds (EM fragility, China weakness, sustained energy disruption) create meaningful downside risk that outweighs the 11-14% upside to $102-105.
EV: -$5 to $10 (8-14% upside vs 7.5% downside, ~1.3:1 risk/reward) · concedes: H1 2026 revenue growth at ~5% IS a genuine reacceleration from 1.4% in FY2025; FY2025 was distorted by $929M non-cash impairment that makes comparisons look better; CL is a high-quality franchise; China's weakness is partly offset by India and other EM markets; Gross margin at 60.1% in 2025 was achieved through pricing power
→ vs conservative: 1.3:1 upside-to-downside ratio is wrong because using wrong floor; 200 SMA at 85.86 is structural floor, not lower Bollinger at 89.86, making actual downside 6.6% vs 8% upside
→ vs conservative: MACD negative cross at minus 0.05 is noise; conservative cited technical report saying one day signal is not a trend and magnitude is tiny
→ vs conservative: Hormuz and EM headwinds are temporary input cost noise being dramatically overweighted relative to structural 310bps gross margin expansion over two years
→ vs conservative: Dividend yield below peer average is weakest argument because sustainable payout ratio and 25+ years of growth makes 2.28% superior to higher-yielding peers at risk of cuts
→ vs neutral: Range-bound consolidation is compression before expansion, not indecision; light volume on pullback is resting, not distribution
→ vs neutral: Wait-for-confirmation framing causes underperformance; buying breakout at 94 instead of 92 gives up 2 points upside plus dividend ex-date
→ vs neutral: Neutral completely misses Q2 reacceleration story from 1.4% to 4.9% revenue growth and the 10-15% multiple expansion potential if Q3 confirms trajectory
→ vs conservative: Both views are focused on what could go wrong in next 30 days, blind to what will compound over next 30 quarters
Market Cap
$73.3B
52-Week High
$99.33
52-Week Low
$74.55
50-Day Moving Avg
$91.31
200-Day Moving Avg
$86.67
Beta
0.327
P/E (TTM)
36.2x
Forward P/E
22.4x
PEG Ratio
1.78
Price/Book
310.6x
Dividend Yield
2.28%
EPS (TTM)
$2.54
Forward EPS
$4.10
Normalized EPS (2024)
$3.51
Revenue 2021
$17.42B
Revenue 2022
$17.97B
Revenue 2023
$19.46B
Revenue 2024
$20.10B
Revenue 2025
$20.38B
Revenue Q2 2026
$5.36B
Gross Margin 2025
60.1%
Operating Margin 2025
20.8%
Net Margin 2025
10.5%
Gross Profit 2025
$12.25B
Operating Income 2025
$4.23B
Net Income 2025
$2.13B
Diluted EPS 2025
$2.63
2025 Impairment Charge
$929M
Other Non-Operating Expenses 2025
$982M
Normalized EBITDA 2025
$4.885B
Normalized EBITDA 2024
$4.859B
Total Assets 2025
$16,330M
Total Debt 2025
$8,554M
Cash 2025
$1,288M
Net Debt 2025
$6,700M
Net Debt 2022
$7.99B
Net Debt 2023
$7.58B
Net Debt 2024
$6.85B
Stockholders' Equity 2025
$54M
Goodwill 2025
$3.12B
Net Debt/EBITDA
1.4x
Current Ratio
1.03
Debt/Equity
1388%
Invested Capital
$8.04B
Working Capital 2025
$-1.14B
Diluted Shares 2022
838.8M
Diluted Shares Q2 2026
801.8M
OCF 2022
$2.556B
OCF 2023
$3.745B
OCF 2024
$4.107B
OCF 2025
$4.198B
CapEx 2025
$564M
FCF 2022
$1.860B
FCF 2023
$3.040B
FCF 2024
$3.546B
FCF 2025
$3.634B
Dividends Paid 2022
~$1.7B
Dividends Paid 2025
$1.823B
Buybacks 2025
$1.210B
Total Returned to Shareholders 2025
$3.033B
Payout Ratio (vs FCF)
~84%
Cumulative Treasury Stock
~$28.45B
H1 2026 OCF
$1.74B
H1 2026 FCF
$1.48B
H1 2026 Buybacks
$597M
H1 2026 Dividends
$879M
Q2 2026 Operating Income
$1.02B
Q2 2026 Net Income
$693M
Q2 2026 Diluted EPS
$0.86
Q2 2026 OCF
$995M
ROE
267%
ROA
15.8%
Strengths
Concerns
Colgate-Palmolive is a high-quality consumer staples defensive holding offering a 2.28% dividend yield (Dividend Aristocrat), strong FCF generation of $3.63B (17.8% margin) that funds ~84% payout of FCF to shareholders, and improving revenue growth that reaccelerated to +4.9% YoY in Q2 2026 from +1.4% in 2025. The company maintains an investment-grade balance sheet (Net Debt/EBITDA ~1.4x) with disciplined deleveraging from $7.99B to $6.70B net debt since 2022, though near-zero book equity ($54M) from aggressive buybacks limits M&A flexibility. The 36.2x TTM P/E is inflated by a one-time $929M impairment; on normalized 2024 EPS of $3.51, the P/E is ~26x, and the forward P/E of 22.4x based on expected $4.10 EPS recovery is reasonable for a defensive name. HOLD rating reflects fair-to-slightly-premium valuation near the 52-week high with limited near-term upside; new entrants should wait for a pullback to $85-87 for better risk/reward.
Macro: The macro environment is cautiously supportive but not benign. The Fed-rate-cut trade is effectively off the table for 2026 (Polymarket: 85% probability of zero cuts; higher-for-longer with rates anchored at restrictive levels). Recession odds are low (US: 8%, UK: 10%, Japan: 26%). Two material crosscurrents pressure consumer staples: (1) US-Iran/Hormuz energy shock lifting input costs, with ~600,000 bpd disrupted and Gulf exports 40% below pre-war levels; (2) China PPI/CPI deflation, with PBoC pricing 82% probability of no rate change. KMB's China diaper warning confirms EM headwinds are sector-wide. Overseas demand outpacing domestic is a partial offset. US zero-rate-cut reality limits multiple expansion for defensive names; the dividend yield is the primary return driver.